12:00 AM
 | 
Dec 08, 2008
 |  BioCentury  |  Strategy

Ranexa in Europe

In contrast to the U.S., where CV Therapeutics Inc. is positioning Ranexa ranolazine as a first-line angina drug, in Europe the company figured it was better off with a second-line claim to avoid being priced against generics.

Ranexa's European label includes a broad second-line indication in angina for patients who aren't adequately treated with current drugs, as well as...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >